BioPharmX Corp fka BPMX

[Whos_Who]

Lock in the Partnership! $ A Year of Talks $

"I want to emphasize that with these strong Phase 2b data in hand, we have many potential funding option and I want to reassure everyone on this call that we're exploring all of them" Anja - Tues. June 13, 2017 call transcript

No Share Increase!
No Reverse Split!
No Executive Compensation!!
"make the most sense for the shareholders"
Anja - Tues. June 13, 2017 call transcript

We continue to evaluate a variety of funding alternatives to support the trial, both dilutive and non-dilutive financing options including strategic partnerships with which we could fund our Phase 3 programs.
Anja - Tues. June 13, 2017 call transcript

"on your press release in the same sentence that you talk about starting the Phase 3, you also talk about exploring with ideal funding alternatives; you know, both dilutive and non-dilutive, as well as strategic. Could you highlight to us some aspects of these three different ways you can fund the Phase 3 program and how are you thinking"

"I think we all know that as we look at fund raising, we need capital to move forward with the Phase 3 trial and as we look at the landscape of way to do that but non-dilutive and dilutive as you describe, right, there are several scenarios that are ahead of us and I think I talked about this in generally before where clearly partnering and licensing and other things of that, that would be a non-dilutive event and those are things that accompany with the new technology and innovative drug platform that we have, clearly always wants to explore and look at. And in parallel to that, as we've done previously leading upto now, we always also look at the capital markets as another alternative for raising funds. So I think we're very conscious and thoughtful about that approach, we are looking at all aspects that make the most sense for the shareholders and for the return for all the investors of the business and we'll continue to do that."
Anja - Tues. June 13, 2017 call transcript

"Considering your experience in this field, especially in this business and in terms of the different options that you have in terms of partnership. What would be most optimal for the management such that you can still maintain the economic value of the asset but at the same time help you out with getting through the program? Is there certain things that you are really looking for that can help?"

"Yes, I think -- and I will first make this -- I think management's interest are completely aligned with our shareholders interest. So as I think everyone on the call knows, I'm the Co-Founder in the company, our management team and I'll go as far as to say our employee base, all have a vested interest in the success in the outcome of our company, whether that's new equity that we made with our own investments or whether that's through stock options of the employee base. So we're very much aligned. So as we look and explore the various options in front of us, I can assure you that management is taking the same eye to this as would other shareholders that are presented with those decisions. Now that's probably about all I can address at the moment because we'll continue to do that, that I can assure everyone on the call that we'll absolutely make the best decisions for all of our investor base."
Anja - Tues. June 13, 2017 call transcript

Longs want to know. Where's the deal?
"make the most sense for the shareholders"
Anja - Tues. June 13, 2017 call transcript


http://www.conferencecalltranscripts.org/include?location=http://seekingalpha.com/article/4081265-biopharmxs-bpmx-q1-2018-results-earnings-call-transcript